Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 872139, 15 pages
http://dx.doi.org/10.1155/2014/872139
Review Article

Glycyrrhizic Acid in the Treatment of Liver Diseases: Literature Review

1Key Laboratory of Liver and Kidney Diseases, Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong New District, Shanghai 201203, China
2Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
3Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA

Received 28 February 2014; Revised 11 April 2014; Accepted 11 April 2014; Published 13 May 2014

Academic Editor: Kota V. Ramana

Copyright © 2014 Jian-yuan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. L. Gujral, K. Sareen, D. P. Phukan, and M. K. Amma, “Anti-arthritic activity of glycyrrhizin in adrenalectomised rats,” Indian Journal of Medical Sciences, vol. 15, pp. 625–629, 1961. View at Google Scholar
  2. A. Kumagai, M. Nanaboshi, Y. Asanuma, T. Yagura, and K. Nishino, “Effects of glycyrrhizin on thymolytic and immunosuppressive action of cortisone,” Endocrinologia Japonica, vol. 14, no. 1, pp. 39–42, 1967. View at Google Scholar · View at Scopus
  3. R. Pompei, O. Flore, M. A. Marccialis, A. Pani, and B. Loddo, “Glycyrrhizic acid inhibits virus growth and inactivates virus particles,” Nature, vol. 281, no. 5733, pp. 689–690, 1979. View at Google Scholar · View at Scopus
  4. Y. Kiso, M. Tohkin, H. Hikino, T. Sakamoto, and T. Namba, “Mechanism of antihepatotoxic activity of glycyrrhizin. I: effect on free radical generation and lipid peroxidation,” Planta Medica, vol. 50, no. 4, pp. 298–302, 1984. View at Google Scholar · View at Scopus
  5. A. L. Leroy, Contribution a' l'étude des propriétés pharmacodynamiques dex extraits de reglisse (Glycyrrhiza glabra kgumineuse) [Thesis], University of Paris, Faculty of Medicine, vol. 592, pp. 1–49, 1959.
  6. C. Nieman, “Pharmacological properties of liquorice,” Chemist and Druggist, vol. 177, pp. 741–745, 1962. View at Google Scholar
  7. W. Logemann, F. Lauria, G. Cudkowicz, and J. Franceschini, “Antileukæmic activity of glycyrrhetinic acid,” Nature, vol. 187, no. 4737, pp. 607–608, 1960. View at Publisher · View at Google Scholar · View at Scopus
  8. J. C. Mirsalis, C. M. Hamilton, J. E. Schindler, C. E. Green, and J. E. Dabbs, “Effects of soya bean flakes and liquorice root extract on enzyme induction and toxicity in B6C3F1 mice,” Food and Chemical Toxicology, vol. 31, no. 5, pp. 343–350, 1993. View at Publisher · View at Google Scholar · View at Scopus
  9. H.-C. Zhang, Y.-X. Song, and Z.-C. Zhang, “Glycyrrhizin administration ameliorates coxsackievirus B3-induced myocarditis in mice,” The American Journal of the Medical Sciences, vol. 344, no. 3, pp. 206–210, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Q. Deng, B. H. May, A. L. Zhang, C. J. Lu, and C. C. L. Xue, “Topical herbal medicine combined with pharmacotherapy for psoriasis: a systematic review and meta-analysis,” Archives of Dermatological Research, vol. 305, no. 3, pp. 179–189, 2013. View at Google Scholar
  11. S. Thiugnanam, L. Xu, K. Ramaswamy, and M. Gnanasekar, “Glycyrrhizin induces apoptosis in prostate cancer cell lines DU-145 and LNCaP,” Oncology Reports, vol. 20, no. 6, pp. 1387–1392, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. F. Chen, P. Xu, S. Y. Zhu, and Y. J. Hu, “Advance in research for pharmacokinetics and drug interactions of licorice,” Chinese Journal of Clinical Pharmacology, vol. 15, no. 10, pp. 1174–1182, 2010. View at Google Scholar
  13. J. P. Yong, “Advances in studies on the synthesis of Glycyrrhizic acid, Glycyrrhetinic acid derivatives and their biological activities,” Lishizhen Medicine and Materia Medica Research, vol. 23, no. 6, pp. 1174–1182, 2012. View at Google Scholar
  14. S. Matsui, H. Matsumoto, Y. Sonoda et al., “Glycyrrhizin and related compounds down-regulate production of inflammatory chemokines IL-8 and eotaxin 1 in a human lung fibroblast cell line,” International Immunopharmacology, vol. 4, no. 13, pp. 1633–1644, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. H.-Y. Park, S.-H. Park, H.-K. Yoon, J. H. Myung, and D.-H. Kim, “Anti-allergic activity of 18β-glycyrrhetinic acid-3-O-β-D-glucuronide,” Archives of Pharmacal Research, vol. 27, no. 1, pp. 57–60, 2004. View at Google Scholar · View at Scopus
  16. Y. Matsumoto, T. Matsuura, H. Aoyagi et al., “Antiviral activity of Glycyrrhizin against Hepatitis C virus in vitro,” PLoS ONE, vol. 8, no. 7, pp. 1–10, 2013. View at Google Scholar
  17. J.-H. Tu, D.-L. Hu, L.-L. Dai et al., “Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes,” Xenobiotica, vol. 40, no. 6, pp. 393–399, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Nishimoto, A. Hisatsune, H. Katsuki, T. Miyata, K. Yokomizo, and Y. Isohama, “Glycyrrhizin attenuates mucus production by inhibition of MUC5AC mRNA expression in vivo and in vitro,” Journal of Pharmacological Sciences, vol. 113, no. 1, pp. 76–83, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Takii, T. Kometani, T. Nishimura, T. Nakae, S. Okada, and T. Fushiki, “Antidiabetic effect of glycyrrhizin in genetically diabetic KK-Ay mice,” Biological and Pharmaceutical Bulletin, vol. 24, no. 5, pp. 484–487, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. C.-X. Zeng, Q.- Yang, and Q.- Hu, “A comparison of the distribution of two glycyrrhizic acid epimers in rat tissues,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 31, no. 4, pp. 253–258, 2006. View at Google Scholar · View at Scopus
  21. M. P. Manns, H. Wedemeyer, A. Singer et al., “Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks,” Journal of Viral Hepatitis, vol. 19, no. 8, pp. 537–546, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Abe, T. Ebina, and N. Ishida, “Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice,” Microbiology and Immunology, vol. 26, no. 6, pp. 535–539, 1982. View at Google Scholar · View at Scopus
  23. S. Yasui, K. Fujiwara, A. Tawada, Y. Fukuda, M. Nakano, and O. Yokosuka, “Efficacy of intravenous glycyrrhizin in the early stage of acute onset autoimmune hepatitis,” Digestive Diseases and Sciences, vol. 56, no. 12, pp. 3638–3647, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Arase, K. Ikeda, N. Murashima et al., “The long term efficacy of Glycyrrhizin in chronic hepatitis C patients,” Cancer, vol. 79, no. 8, pp. 1494–1500, 1997. View at Google Scholar
  25. K. Ikeda, “Glycyrrhizin injection therapy prevents hepatocellular carcinogenesis in patients with interferon-resistant active chronic hepatitis C,” Hepatology Research, vol. 37, no. 2, pp. S287–S293, 2007. View at Google Scholar
  26. H.-F. Wang, H.-B. Su, H.-L. Liu et al., “Clinical research on treatment on several kinds of liver hepatitis with diammonium glycyrrhizinate,” Chinese Journal of Infectious Diseases, vol. 22, no. 2, pp. 113–115, 2004. View at Google Scholar
  27. Y. Cao, X.-Y. Tang, and F.-W. Song, “Compare of and beta-Glycyrrhetinic acid alpha-Glycyrrhetinic acid in the treatment of Chronic Hepatitis B,” China Journal of Modern Medicine, vol. 12, no. 7, pp. 91–92, 2002. View at Google Scholar
  28. Q.-T. Xu, “Clinical observation of magnesium isoglycyrrhizinate in the treatment of chronic hepatitis B,” Journal of Clinical Hepatology, vol. 23, no. 4, pp. 282–283, 2007. View at Google Scholar
  29. X.-J. Shen, Z.-L. Liu, and Y.-Z. Xue, “Observation of magnesium isoglycyrrhizinate in the treatment of chronic severe hepatitis,” Journal of Clinical Medicine in Practice, vol. 11, no. 6, pp. 71–72, 2007. View at Google Scholar
  30. H.-C. Ni, Y.-Y. Qi, and W.-D. Feng, “Effect of magnesium isoglycyrrhizinate in the treatment of the hepatotoxicity caused by anti-tumor agents in cancer patients,” Anhui Medical and Pharmaceutical Journal, vol. 13, no. 9, pp. 1099–1100, 2009. View at Google Scholar
  31. T. Genovese, M. Menegazzi, E. Mazzon et al., “Glycyrrhizin reduces secondary inflammatory process after spinal cord compression injury in mice,” Shock, vol. 31, no. 4, pp. 367–375, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Lin, Y. Liu, Y. Huang et al., “Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery,” International Journal of Pharmaceutics, vol. 359, no. 1-2, pp. 247–253, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Korenaga, I. Hidaka, S. Nishina et al., “A glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis C virus protein and iron in mice,” Liver International, vol. 31, no. 4, pp. 552–560, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. G.-Q. Zang, X.-Q. Zhou, H. Yu et al., “Effect of hepatocyte apoptosis induced by TNF-α on acute severe hepatitis in mouse models,” World Journal of Gastroenterology, vol. 6, no. 5, pp. 688–692, 2000. View at Google Scholar · View at Scopus
  35. M. Rivero, J. Crespo, E. Fábrega et al., “Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus,” Journal of Viral Hepatitis, vol. 9, no. 2, pp. 107–113, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. C. J. McClain, “Tumor necrosis and alcoholic hepatitis,” Hepatology, vol. 14, no. 2, pp. 394–396, 1991. View at Google Scholar
  37. D. R. Green, “Apoptotic pathways: paper wraps stone blunts scissors,” Cell, vol. 102, no. 1, pp. 1–4, 2000. View at Google Scholar · View at Scopus
  38. N. F. El-Tahawy, A. H. Ali, S. R. Saied, and Z. A. Wahab, “Effect of glycyrrhizin on lipopolysaccharide/D-galactosamine-induced acute hepatitis in albino rats: a histological and immunohistochemical study,” The Egyptian Journal of Histology, vol. 34, no. 3, pp. 518–527, 2011. View at Google Scholar
  39. B. Tang, H. Qiao, F. Meng, and X. Sun, “Glycyrrhizin attenuates endotoxin-induced acute liver injury after partial hepatectomy in rats,” Brazilian Journal of Medical and Biological Research, vol. 40, no. 12, pp. 1637–1646, 2007. View at Google Scholar · View at Scopus
  40. C.-C. Hu, W.-K. Chen, P.-H. Liao, W.-C. Yu, and Y.-J. Lee, “Synergistic effect of cadmium chloride and acetaldehyde on cytotoxicity and its prevention by quercetin and glycyrrhizin,” Mutation Research: Genetic Toxicology and Environmental Mutagenesis, vol. 496, no. 1-2, pp. 117–127, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. C.-L. Zhai, M.-Q. Zhang, Y. Zhang et al., “Glycyrrhizin protects rat heart against ischemia-reperfusion injury through blockade of HMGB1-dependent phospho-JNK/Bax pathway,” Acta Pharmacologica Sinica, vol. 33, no. 12, pp. 1477–1487, 2012. View at Google Scholar
  42. B. Ni, Z. Y. Cao, and Y. Liu, “Glycyrrhizin protects spinal cord and reduces inflammation in spinal cord ischemia-reperfusion injury,” International Journal of Neuroscience, vol. 123, no. 11, pp. 745–751, 2013. View at Google Scholar
  43. M. Ogiku, H. Kono, M. Hara, M. Tsuchiya, and H. Fujii, “Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by kupffer cells after ischemia-reperfusion in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 339, no. 1, pp. 93–98, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Rahman and S. Sultana, “Chemopreventive activity of glycyrrhizin on lead acetate mediated hepatic oxidative stress and its hyperproliferative activity in Wistar rats,” Chemico-Biological Interactions, vol. 160, no. 1, pp. 61–69, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. C.-T. Tu, J. Li, F.-P. Wang, L. Li, J.-Y. Wang, and W. Jiang, “Glycyrrhizin regulates CD4+T cell response during liver fibrogenesis via JNK, ERK and PI3K/AKT pathway,” International Immunopharmacology, vol. 14, no. 4, pp. 410–421, 2012. View at Google Scholar
  46. H. Honda, Y. Nagai, T. Matsunaga et al., “Glycyrrhizin and isoliquiritigenin suppress the LPS sensor Toll-like receptor 4/MD-2 complex signaling in a different manner,” Journal of Leukocyte Biology, vol. 91, no. 6, pp. 967–976, 2012. View at Google Scholar
  47. B. Schröfelbauer, J. Raffetseder, M. Hauner, A. Wolkerstorfer, W. Ernst, and O. H. J. Szolar, “Glycyrrhizin, the main active compound in liquorice, attenuates pro-inflammatory responses by interfering with membrane-dependent receptor signalling,” Biochemical Journal, vol. 421, pp. 473–482, 2009. View at Google Scholar · View at Scopus
  48. Y. Fujisawa, M. Sakamoto, M. Matsushita, T. Fujita, and K. Nishioka, “Glycyrrhizin inhibits the lytic pathway of complement: possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis,” Microbiology and Immunology, vol. 44, no. 9, pp. 799–804, 2000. View at Google Scholar · View at Scopus
  49. M. Takei, M. Kobayashi, D. N. Herndon, R. B. Pollard, and F. Suzuki, “Glycyrrhizin inhibits the manifestations of anti-inflammatory responses that appear in association with systemic inflammatory response syndrome (SIRS)-like reactions,” Cytokine, vol. 35, no. 5-6, pp. 295–301, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Menegazzi, R. Di Paola, E. Mazzon et al., “Glycyrrhizin attenuates the development of carrageenan-induced lung injury in mice,” Pharmacological Research, vol. 58, no. 1, pp. 22–31, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Cinatl, B. Morgenstern, G. Bauer, P. Chandra, H. Rabenau, and H. W. Doerr, “Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus,” The Lancet, vol. 361, no. 9374, pp. 2045–2046, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. U. A. Ashfaq, M. S. Masoud, Z. Nawaz, and S. Riazuddin, “Glycyrrhizin as antiviral agent against Hepatitis C Virus,” Journal of Translational Medicine, vol. 9, no. 1, article 112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Xu, X. Zhang, and J. Yang, “Effects of glycyrrhizin on biliary transport and hepatic levels of glutathione in rats,” Biopharmaceutics and Drug Disposition, vol. 33, no. 5, pp. 235–245, 2012. View at Google Scholar
  54. J. König, A. T. Nies, Y. Cui, I. Leier, and D. Keppler, “Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance,” Biochimica et Biophysica Acta: Biomembranes, vol. 1461, no. 2, pp. 377–394, 1999. View at Publisher · View at Google Scholar · View at Scopus
  55. X.-J. Liang and A. Aszalos, “Multidrug transporters as drug targets,” Current Drug Targets, vol. 7, no. 8, pp. 911–921, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Masuda, Y. I'izuka, M. Yamazaki et al., “Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats,” Cancer Research, vol. 57, no. 16, pp. 3506–3510, 1997. View at Google Scholar · View at Scopus
  57. A. Morikawa, Y. Goto, H. Suzuki, T. Hirohashi, and Y. Sugiyama, “Biliary excretion of 17β-estradiol 17β-D-glucuronide is predominantly mediated by cMOAT/MRP2,” Pharmaceutical Research, vol. 17, no. 5, pp. 546–552, 2000. View at Google Scholar · View at Scopus
  58. H. Sun, Y.-Y. Zeng, and K.-S. Pang, “Interplay of phase II enzymes and transporters in futile cycling: influence of multidrug resistance-associated protein 2-mediated excretion of estradiol 17β-D-glucuronide and its 3-sulfate metabolite on net sulfation in perfused TR- and wistar rat liver preparations,” Drug Metabolism and Disposition, vol. 38, no. 5, pp. 769–780, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. J.-H. Dai, Y. Iwatani, T. Ishida et al., “Glycyrrhizin enhances interleukin-12 production in peritoneal macrophages,” Immunology, vol. 103, no. 2, pp. 235–243, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Mori, H. Sakai, S. Suzuki et al., “Effects of glycyrrhizin (SNMC: stronger neo-minophagen C) in hemophilia patients with HIV-1 infection,” Tohoku Journal of Experimental Medicine, vol. 162, no. 2, pp. 183–193, 1990. View at Google Scholar · View at Scopus
  61. C. Miyaji, R. Miyakawa, H. Watanabe, H. Kawamura, and T. Abo, “Mechanisms underlying the activation of cytotoxic function mediated by hepatic lymphocytes following the administration of glycyrrhizin,” International Immunopharmacology, vol. 2, no. 8, pp. 1079–1086, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. H. Sato, S. Kageyama, H. Yamamoto et al., “Glycyrrhizin renders cells resistant to apoptosis induced by human and feline immunodeficiency virus,” Journal of Traditional Medicines, vol. 28, no. 3, pp. 139–148, 2011. View at Google Scholar
  63. K. Ohuchi, Y. Kamada, L. Levine, and S. Tsurufuji, “Glycyrrhizin inhibits prostaglandin E2 production by activated peritoneal macrophages from rats,” Prostaglandins and Medicine, vol. 7, no. 5, pp. 457–463, 1981. View at Google Scholar · View at Scopus
  64. R. Pompei, O. Flore, and M. A. Marccialis, “Glycyrrhizic acid inhibits virus growth and inactivates virus particles,” Nature, vol. 281, no. 5733, pp. 689–690, 1979. View at Google Scholar · View at Scopus
  65. H. Y. Park, S. H. Park, H. K. Yoon, M. J. Han, and D. H. Kim, “Anti-allergic activity of 18 beta-glycyrrhetinic acid-3-O-beta-D-glucuronide,” Archives of Pharmacal Research, vol. 27, no. 1, pp. 57–60, 2004. View at Google Scholar
  66. S. Tanaka, C. Uno, M. Akimoto, M. Tabata, C. Honda, and W. Kamisako, “Anti-allergic effect of bryonolic acid from Luffa cylindrica cell suspension cultures,” Planta Medica, vol. 57, no. 6, pp. 527–530, 1991. View at Google Scholar · View at Scopus
  67. Z. Kawakami, Y. Ikarashi, and Y. Kase, “Glycyrrhizin and its metabolite 18β-glycyrrhetinic acid in glycyrrhiza, a constituent herb of yokukansan, ameliorate thiamine deficiency-induced dysfunction of glutamate transport in cultured rat cortical astrocytes,” European Journal of Pharmacology, vol. 626, no. 2-3, pp. 154–158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. X. Zhu, C. Chen, D. Ye et al., “Diammonium glycyrrhizinate upregulates PGC-1α and protects against Aβ1-42-induced neurotoxicity,” PLoS ONE, vol. 7, no. 4, Article ID e35823, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. J.-Y. Shim, S.-B. Yim, J.-H. Chung, and K.-S. Hong, “Antiplaque and antigingivitis effects of a mouthrinse containing cetylpyridinium chloride, triclosan and dipotassium glycyrrhizinate,” Journal of Periodontal and Implant Science, vol. 42, no. 2, pp. 33–38, 2012. View at Google Scholar
  70. H.-X. Gao, S.-H. Shao, and G.-Q. Wang, “Research progress of Radix Glycyrrhizae,” Journal of Jinggangshan Medical College, vol. 11, no. 5, pp. 8–11, 2004. View at Google Scholar
  71. X.-L. Li and A.-G. Zhou, “Evaluation of the immunity activity of glycyrrhizin in AR mice,” Molecules, vol. 17, no. 1, pp. 716–727, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. V. P. Makarenkova, V. Bansal, B. M. Matta, L. A. Perez, and J. B. Ochoa, “CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress,” Journal of Immunology, vol. 176, no. 4, pp. 2085–2094, 2006. View at Google Scholar · View at Scopus
  73. L. Steinstraesser, C. Schubert, F. Jacobsen, and S. Al-Benna, “Glycyrrhizin against multi-resistant bacteria?” Journal of Leukocyte Biology, vol. 87, no. 1, pp. 7–8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. T. Utsunomiya, M. Kobayashi, M. Ito, D. N. Herndon, R. B. Pollard, and F. Suzuki, “Glycyrrhizin restores the impaired IL-12 production in thermally injured mice,” Cytokine, vol. 14, no. 1, pp. 49–55, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. Y.-H. Zhang, K. Isobe, F. Nagase et al., “Glycyrrhizin as a promoter of the late signal transduction for interleukin-2 production by splenic lymphocytes,” Immunology, vol. 79, no. 4, pp. 528–534, 1993. View at Google Scholar · View at Scopus
  76. X.-L. Li, A.-G. Zhou, L. Zhang, and W.-J. Chen, “Antioxidant status and immune activity of glycyrrhizin in allergic rhinitis mice,” International Journal of Molecular Sciences, vol. 12, no. 2, pp. 905–916, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Michaelis, J. Geiler, P. Naczk et al., “Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression,” PLoS ONE, vol. 6, no. 5, Article ID e19705, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Paolini, J. Barillari, M. Broccoli, L. Pozzetti, P. Perocco, and G. Cantelli-Forti, “Effect of liquorice and glycyrrhizin on rat liver carcinogen metabolizing enzymes,” Cancer Letters, vol. 145, no. 1-2, pp. 35–42, 1999. View at Publisher · View at Google Scholar · View at Scopus
  79. H.-T. Chan, C. Chan, and J.-W. Ho, “Inhibition of glycyrrhizic acid on aflatoxin B1-induced cytotoxicity in hepatoma cells,” Toxicology, vol. 188, no. 2-3, pp. 211–217, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. L.-L. Shi, C. Tang, and C.-H. Yin, “Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma,” Biomaterials, vol. 33, no. 30, pp. 7594–7604, 2012. View at Google Scholar
  81. G. Shiota, K.-I. Harada, M. Ishida et al., “Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice,” Carcinogenesis, vol. 20, no. 1, pp. 59–63, 1999. View at Publisher · View at Google Scholar · View at Scopus
  82. J.-H. Tu, Y.-J. He, Y. Chen et al., “Effect of glycyrrhizin on the activity of CYP3A enzyme in humans,” European Journal of Clinical Pharmacology, vol. 66, no. 8, pp. 805–810, 2010. View at Google Scholar
  83. B. A. Carneiro-Filho, I. P. F. Lima, D. H. Araujo et al., “Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis,” Digestive Diseases and Sciences, vol. 49, no. 1, pp. 65–72, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. S.-P. Lin, S.-Y. Tsai, Y.-C. Hou, and P.-D. L. Chao, “Glycyrrhizin and licorice significantly affect the pharmacokinetics of methotrexate in rats,” Journal of Agricultural and Food Chemistry, vol. 57, no. 5, pp. 1854–1859, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. W. E. Evans, W. R. Crom, and M. Abromowitch, “Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect,” The New England Journal of Medicine, vol. 314, no. 8, pp. 471–476, 1986. View at Google Scholar · View at Scopus
  86. M. Tishler, D. Caspi, and M. Yaron, “Long-term experience with low dose methotrexate in rheumatoid arthritis,” Rheumatology International, vol. 13, no. 3, pp. 103–106, 1993. View at Publisher · View at Google Scholar · View at Scopus
  87. J. Chladek, J. Grim, J. Martinkova, M. Simkova, and J. Vaneckova, “Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis,” Basic and Clinical Pharmacology and Toxicology, vol. 96, no. 3, pp. 247–248, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. A. L. A. Kuijpers and P. C. M. van de Kerkhof, “Risk-benefit assessment of methotrexate in the treatment of severe psoriasis,” The American Journal of Clinical Dermatology, vol. 1, no. 1, pp. 27–39, 2000. View at Google Scholar · View at Scopus
  89. Y. Maeda, N. Inaba, M. Aoyagi, T. Tanase, and T. Shiigai, “Pseudoaldosteronism caused by combined administration of cilostazol and glycyrrhizin,” Internal Medicine, vol. 47, no. 14, pp. 1345–1348, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. T. Zenone and Q. Blanc, “Rhabdomyolysis with major hypokalemia secondary to chronic glycyrrhizic acid ingestion,” Revue de Medecine Interne, vol. 30, no. 1, pp. 78–80, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. R. K. Støving, L. E. Lingqvist, R. K. Bonde et al., “Is glycyrrhizin sensitivity increased in anorexia nervosa and should licorice be avoided? Case report and review of the literature,” Nutrition, vol. 27, no. 7-8, pp. 855–858, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Sen, M. Roy, and A. S. Chakraborti, “Ameliorative effects of glycyrrhizin on streptozotocin-induced diabetes in rats,” Journal of Pharmacy and Pharmacology, vol. 63, no. 2, pp. 287–296, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. D.-G. Kang, E.-J. Sohn, and H.-S. Lee, “Effects of glycyrrhizin on renal functions in association with the regulation of water channels,” The American Journal of Chinese Medicine, vol. 31, no. 3, pp. 403–413, 2003. View at Publisher · View at Google Scholar · View at Scopus
  94. D.-G. Kang, E.-J. Sohn, Y.-J. Mun, W.-H. Woo, and H.-S. Lee, “Glycyrrhizin ameliorates renal function defects in the early-phase of ischemia-induced acute renal failure,” Phytotherapy Research, vol. 17, no. 8, pp. 947–951, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. Y. Lee, S. Jeong, W. Kim et al., “Glycyrrhizin enhances therapeutic activity of a colon-specific methylprednisolone prodrug against experimental colitis,” Digestive Diseases and Sciences, vol. 58, no. 5, pp. 1226–1234, 2013. View at Google Scholar
  96. T. Rossi, L. Benassi, C. Magnoni, A. I. Ruberto, A. Coppi, and G. Baggio, “Effects of glycyrrhizin on UVB-irradiated melanoma cells,” In Vivo, vol. 19, no. 1, pp. 319–322, 2005. View at Google Scholar · View at Scopus
  97. A. B. Hocaoglu, O. Karaman, D. O. Erge et al., “Glycyrrhizin and long-term histopathologic changes in a murine model of asthma,” Current Therapeutic Research: Clinical and Experimental, vol. 72, no. 6, pp. 250–261, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. A. Ram, U. Mabalirajan, M. Das et al., “Glycyrrhizin alleviates experimental allergic asthma in mice,” International Immunopharmacology, vol. 6, no. 9, pp. 1468–1477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. Y.-F. Ni, J.-K. Kuai, Z.-F. Lu et al., “Glycyrrhizin treatment is associated with attenuation of lipopolysaccharide-induced acute lung injury by inhibiting cyclooxygenase-2 and inducible nitric oxide synthase expression,” Journal of Surgical Research, vol. 165, no. 1, pp. e29–e35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. M. L. Parisella, T. Angelone, A. Gattuso, M. C. Cerra, and D. Pellegrino, “Glycyrrhizin and glycyrrhetinic acid directly modulate rat cardiac performance,” Journal of Nutritional Biochemistry, vol. 23, no. 1, pp. 69–75, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. Y. J. Kim and C. S. Lee, “Glycyrrhizin attenuates MPTP neurotoxicity in mouse and MPP+-induced cell death in PC12 cells,” Korean Journal of Physiology and Pharmacology, vol. 12, no. 2, pp. 65–71, 2008. View at Google Scholar · View at Scopus
  102. J. H. Song, J. W. Lee, B. Shim, and C. Y. Lee, “Glycyrrhizin alleviates neuroinflammation and memory deficit Induced by systemic lipopolysaccharide treatment in mice,” Molecules, vol. 18, no. 12, pp. 15788–15803, 2013. View at Google Scholar
  103. Z. Song, Y. Gong, H. Liu, Q. Ren, and X. Sun, “Glycyrrhizin could reduce ocular hypertension induced by triamcinolone acetonide in rabbits,” Molecular Vision, vol. 17, pp. 2056–2064, 2011. View at Google Scholar · View at Scopus
  104. T. Utsunomiya, M. Kobayashi, M. Ito, R. B. Pollard, and F. Suzuki, “Glycyrrhizin improves the resistance of MAIDS mice to opportunistic infection of Candida albicans through the modulation of MAIDS-associated type 2 T cell responses,” Clinical Immunology, vol. 95, no. 2, pp. 145–155, 2000. View at Publisher · View at Google Scholar · View at Scopus
  105. T. Yoshida, Y. Tsuda, D. Takeuchi, M. Kobayashi, R. B. Pollard, and F. Suzuki, “Glycyrrhizin inhibits neutrophil-associated generation of alternatively activated macrophages,” Cytokine, vol. 33, no. 6, pp. 317–322, 2006. View at Publisher · View at Google Scholar · View at Scopus
  106. Y.-M. Mao, M.-D. Zeng, Y. Chen et al., “Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study,” Zhonghua Gan Zang Bing Za Zhi, vol. 17, no. 11, pp. 847–851, 2009. View at Google Scholar · View at Scopus
  107. Z.-W. Xiao, W. Zhang, L. Ma, and Z.-W. Qiu, “Therapeutic effect of magnesium isoglycyrrhizinate in rats on lung injury induced by paraquat poisoning,” European Review for Medical and Pharmacological Sciences, vol. 18, no. 3, pp. 311–320, 2014. View at Google Scholar
  108. J. Zhao, X.-Y. Wan, M. Luo, T.-S. Chen, and P. He, “Antifibrotic effects of glycyrrhizin and matrine in vitro and in vivo,” Biomedicine and Preventive Nutrition, vol. 2, no. 2, pp. 132–137, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. X.-Y. Wan, M. Luo, X.-D. Li, and P. He, “Hepatoprotective and anti-hepatocarcinogenic effects of glycyrrhizin and matrine,” Chemico-Biological Interactions, vol. 181, no. 1, pp. 15–19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. C.-A. Ren, Y.-X. Li, and J.-Y. Cui, “Efficacy of glycyrrhizin combined with cyclosporine in the treatment of non-severe aplastic anemia,” Chinese Medical Journal, vol. 126, no. 11, pp. 2083–2086, 2013. View at Google Scholar
  111. Y.-Q. Meng, J.-Q. Ding, Y. Liu, H.-H. Nie, S. Guan et al., “Synthesis and anti-tumor activity of novel glycyrrhetinic acid derivatives,” Chemical Research in Chinese Universities, vol. 28, no. 2, pp. 214–219, 2012. View at Google Scholar
  112. Y. Mizushina, T. Ishida, S. Yagi et al., “Inhibitory effects of glycyrrhetinic acid on DNA polymerase and inflammatory activities,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 650514, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. R. Mencucci, E. Favuzza, and U. Menchini, “Assessment of the tolerability profile of an ophthalmic solution of 5% glycyrrhizin and copolymer PEG PPG on healthy volunteers and evaluation of its efficacy in the treatment of moderate to severe blepharitis,” Clinical Ophthalmology, vol. 7, pp. 1403–1410, 2013. View at Google Scholar
  114. M. E. Hardy, J. M. Hendricks, J. M. Paulson, and N. R. Faunce, “18 β-glycyrrhetinic acid inhibits rotavirus replication in culture,” Virology Journal, vol. 9, no. 96, pp. 1–7, 2012. View at Google Scholar